CommonHealth CommonHealth

Support the news

Venture Capital Firm Partner: 'There's No Better Time To Do Drug Discovery' For Cancer Treatments05:06

This article is more than 3 years old.

Young biotech companies that find there are many costs associated with the extensive research needed to test new drugs often look to venture capital firms, like Third Rock Ventures in Boston, to fund their innovations.

One of the firm's partners, Dr. Bob Tepper, joined Morning Edition to talk about why investors would choose to put their money in cancer research despite the high risk of failure.

Correction: An earlier version of this post misstated Tepper's role in Third Rock Ventures. 

This article was originally published on February 01, 2017.

This segment aired on February 1, 2017.


Bob Oakes Twitter Host, Morning Edition
Bob Oakes has been WBUR's Morning Edition anchor since 1992.


Yasmin Amer Twitter Producer, Kind World
Yasmin Amer is a producer and reporter for WBUR’s Kind World podcast.


Support the news